Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting
Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
CURE2d
First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell Lung Cancer
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
EurekAlert!2d
Inhibition of PCSK9: a promising enhancer for anti-PD-1/PD-L1 immunotherapy
Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...
Targeted Oncology13d
Kato Breaks Down FDA Approval of Tislelizumab in Esophageal Cancer
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
The American Journal of Managed Care24d
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Tislelizumab, combined with chemotherapy, is now FDA-approved for first-line treatment of unresectable or metastatic ESCC with PD-L1 expression ... esophageal squamous cell carcinoma (ESCC ...
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...
Business Wire13d
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD ...
Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.
Targeted Oncology14d
Experts Discuss Tislelizumab’s FDA Approval in Esophageal Cancer
Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for ...
Longview News-Journal16d
PD-L1 Measured by Blood Test Reveals Important Clinical Information
The PD-L1 expression is determined by the LifeTracDx ® blood test, which captures Circulating Tumor Cells (CTCs) and Cancer Associated Macrophage-Like cells (CAMLs) by staining the cells for PD ...